The Two 'Brush-Off' Stocks Wall Street Still Targets for Big Upside: PACB vs LEU

Same bell, same clock, one question: when a stock screen and a Wall Street price target disagree, which do you trust — the receipt or the hope?

That is the real bet hiding inside a headline like "1 of Wall Street's Favorite Stocks to Own for Decades and 2 We Brush Off." Skip past the one name the piece loves (VSE Corp, an aircraft-and-vehicle parts-and-repair business carrying a roughly $270 consensus target) and the whole duel sits in the two it brushed off: Pacific Biosciences and Centrus Energy. Wall Street's targets on those two imply about 50% and 30% upside respectively. A fundamentals screen says sell both. Both of those cannot be steering you the same way.

So I'm freezing the two brushed-off names into a card. PACB versus LEU, each set to 100 paper points at the September 4 close, scored on total return over the next twelve months. Neither stock pays a dividend, so total return and price return are the same thing — no distribution drift to reconcile. I'll open the editorial odds at 55/45 in LEU's favor, not because its target will land but because it holds the stronger defense. Quarterly earnings are the checkpoints; a merger, delisting, or capital event trips the written exit rule. This is a paper race: no money, no holdings, no forecast — just a cleaner way to see which scoring system is pricing reality.

Round one: PACB, the hope that ran low on cash

Pacific Biosciences sells high-fidelity long-read gene sequencing. The technology is real; the commercial case is in a lurch. The latest quarter brought in $39 million in revenue, driven by new instrument placements and the rollout of its SPRQ chemistry, and the company was picked by Basecamp Research to power a "Trillion Gene Atlas". That is genuine product traction. Then come the screen's numbers: revenue up a little over 2% from the year before, an operating margin near minus 83%, free cash flow margin around minus 76%, and return on invested capital near minus 20%. The market cap sits around $404 million while the enterprise value runs to roughly $811 million — meaning net debt of about $400 million towers over the equity.

The critique in the original piece was blunt: sales down over the prior two years, negative free cash flow, and a short runway that raises the odds of a dilutive capital raise. For the analyst target to become real, PACB needs revenue to reaccelerate and margins to flip from deeply negative while surviving without printing a pile of new shares. That is a turnaround and a financing in one ticket.

Round two: LEU, the strategic asset at a rich price

Centrus is the only U.S. facility licensed to produce HALEU, the high-assay fuel designed for next-generation reactors. The piece brushed it off for small-company logic: a modest revenue base, gross margins in the mid-20s by the recent data, and an EBITDA margin it argued had sagged. But the economics have the opposite shape from PACB's. LEU is genuinely profitable on a trailing basis — roughly 70x trailing and about 30x forward earnings, which are multiples, not losses. Second-quarter revenue came in at $176.1 million against $154.5 million a year earlier, and the company disclosed a signed $900 million HALEU contract.

The problem is price, not survival: about 7x sales, an enterprise value well over 150x EBITDA, and a capex build steep enough that free cash flow has turned negative. You are paying a scarcity premium for one licensed facility and buying a commodity — uranium — whose price swings move the stock in both directions. It is down about 30% this year, roughly matching PACB's drawdown, even though the underlying business makes money.

Why this is a fair fight, not a stump speech

The screen and the target measure different time zones. A trailing screen is a receipt for what already happened; a price target is an expectation of what must go right. PACB's implies roughly a doubling but only if revenue reaccelerates and cash losses flip from a base that burns money today. LEU's implies a smaller 30% but on a company that already earns net profit — the question is whether you want to pay 70x trailing earnings and inherit the uranium cycle.

On the mechanism board, LEU leads: a working profit-and-loss statement plus a signed large contract beats a turnaround proposal. On optionality, PACB leads: a tiny market cap that manages to reaccelerate moves a long way. The scoreboard can separate from the mechanism — LEU could win the twelve months on catalysts it has already shipped, or PACB could catch an adoption wave and blow past it. That discrepancy is why the odds are 55/45 and not 90/10.

The first checkpoint is the next quarterly report, when I update both normalized scores and log any capital event on the ledger. What this race is really testing is simpler than either stock: whether a price target is a reason to buy, or just a number telling you how much has to go right. Run these two from the same bell long enough, and you find out which system earns its keep.